| Species |
Human |
| Protein Construction |
DR6/TNFRSF21 (Gln42-His349)
Accession # O75509 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized DR6/TNFRSF21, His, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiDR6 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
34.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
beta-amyloid precursor protein (APP) and death receptor 6 (DR6, also known as TNFRSF21) activate a widespread caspase-dependent self-destruction program. DR6 is broadly expressed by developing neurons, and is required for normal cell body death and axonal pruning both in vivo and after trophic-factor deprivation in vitro.DR6 is activated locally by an inactive surface ligand(s) that is released in an active form after trophic-factor deprivation. |
| Synonyms |
Death receptor 6; CD358; TNFRSF21; DR6; BM-018; MGC31965 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
